A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses

Abstract Vaccination is considered to be one of the most effective tools to decrease morbidity as well as mortality caused by influenza viruses.

[1]  V. Ferro.  Improved design of the annual influenza vaccine using epitope analysis , 2005 .

[2]  M. Garcés-Sánchez,et al.  Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3–9 Years: A Phase II Study , 2008 .

[3]  R. Webster,et al.  H5N1 influenza--continuing evolution and spread. , 2006, The New England journal of medicine.

[4]  A. Osterhaus,et al.  Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.

[5]  E. D'hondt,et al.  Immune response to influenza vaccination , 1994, The Lancet.

[6]  Y. Kanegae,et al.  Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season , 1990, Journal of virology.

[7]  M. Deem,et al.  Epitope analysis for influenza vaccine design. , 2004, Vaccine.

[8]  P. Gillard.  Immunogenicity Evaluation of an AS03-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3-9 Years , 2008 .

[9]  R. Schmidt-Ott,et al.  Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. , 2007, Vaccine.

[10]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[11]  A. Kendal,et al.  Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. , 1992, The Journal of general virology.

[12]  T. Vesikari.  Efficacy of an Inactivated Split-Virus Influenza Vaccine , 2008 .

[13]  J. Taubenberger,et al.  Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Cox,et al.  Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice , 2005, Scandinavian journal of immunology.

[15]  J. Wood,et al.  Reference viruses for seasonal and pandemic influenza vaccine preparation , 2006, Influenza and other respiratory viruses.

[16]  V. Prikazsky,et al.  Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. , 1996, Gerontology.

[17]  D. Skowronski,et al.  Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. , 2007, Vaccine.

[18]  Carol A. McCarthy,et al.  Influenza vaccines , 1965, The Medical letter on drugs and therapeutics.

[19]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[20]  C. Cooper,et al.  Fluarix™, inactivated split-virus influenza vaccine , 2006, Expert opinion on biological therapy.

[21]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[22]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[23]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[24]  W. Künzel,et al.  Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. , 1996, Vaccine.

[25]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[26]  E. Neumeier,et al.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines , 2002, Medical Microbiology and Immunology.

[27]  A. Osterhaus,et al.  Pre- or post-pandemic influenza vaccine? , 2007, Vaccine.

[28]  A. Hay,et al.  Recent changes among human influenza viruses. , 2004, Virus research.

[29]  E. Neumeier,et al.  Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. , 2004, Virus research.

[30]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[31]  G. Leroux-Roels,et al.  Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine , 2008, PloS one.

[32]  C. V. Hoecke,et al.  Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™ , 2002 .

[33]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[34]  K. Nichol,et al.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. , 2003, Vaccine.

[35]  J. Richardus,et al.  Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. , 2008, Vaccine.

[36]  J. Langley,et al.  Prevention of influenza in the general population , 2004, Canadian Medical Association Journal.

[37]  W. Keitel,et al.  Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States , 2005, Human vaccines.

[38]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[39]  A. Kendal,et al.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. , 1990, Virology.

[40]  R. Duma.  The National Foundation for Infectious Diseases. , 1976, The Journal of infectious diseases.